Recovery
Recovery + Sleep
BPC-157 for tissue repair, DSIP for sleep depth. The Playbook uses this pairing as its textbook example of non-overlapping mechanisms: two different systems, no shared pathway.
At a glance
- Sold as
- Separate vials
- The evidence
- Zero interaction data. The Playbook lists this combination explicitly with "zero interaction data" against it. The logic is sound, with different targets and no mechanistic overlap, but nobody has studied the two together. Treat it as theoretical.Combination-specific research is limited. Treat each compound’s evidence as separate unless a study of the combination itself is named here, and review the complete plan with a qualified clinician.
Running this stack, with the schedule, the vials it takes and a log of what you took, happens in the app: Claritide for iPhone.
Why people explore it
Common reasons for exploring it
- People who have already run one of these compounds solo successfully and want to add the second
- Injury recovery where poor sleep is genuinely holding back the repair
- Anyone who wants a worked example of principled stacking rather than a Reddit protocol
Where clinician input matters
- First-time peptide users. Run one compound alone for two weeks minimum before considering a second.
- Anyone unwilling to get baseline and week-8 bloodwork
- Anyone on benzodiazepines, CNS depressants, ACE inhibitors or blood pressure medication
- Anyone on therapeutic anticoagulation or with a known bleeding disorder
- Active or recent cancer, pregnancy or nursing, under 25
The science
Read the compound mechanisms
BPC-157 appears to work by improving the blood supply to damaged tissue and then telling the repair machinery to switch on. It increases expression of VEGFR2, a receptor that drives angiogenesis, the growth of new blood vessels, so more oxygen and nutrients reach the injury. It also interacts with the nitric oxide system, which controls how wide blood vessels open and how strongly the inflammatory response fires, counteracting both too little and too much nitric oxide. Separately it raises growth hormone receptor expression in tendon fibroblasts and activates the FAK-paxillin pathway, the signalling route cells use to stick, crawl and divide during wound repair. It is named for a cytoprotective effect: shielding tissue from NSAIDs, alcohol and other stressors. That effect is most pronounced in the gut.
DSIP works on sleep architecture rather than sleep timing. It increases delta-wave (0.5–4 Hz) brain activity, which defines Stage 3 NREM sleep, the phase where growth hormone secretion peaks, cellular repair happens and the brain clears waste. It does not simply add sleep hours; it reorganises the proportion of the night spent in deep sleep. It also modulates the HPA axis, the hormonal chain that produces cortisol and ACTH, which helps normalise the elevated evening cortisol that drives both sleep-onset insomnia and early waking. Its effect on GABA, the brain's main calming neurotransmitter, is indirect: it appears to make GABA-A receptors more sensitive rather than binding them directly the way a benzodiazepine does, which is the standard explanation for why no tolerance or dependency has been observed. A recurring finding is that DSIP is context-sensitive: strong effects when sleep is already broken, minimal effect in healthy sleepers.
Commonly researched ranges
| Compound | Amount | Frequency | Timing |
|---|---|---|---|
| BPC-157 | 250–500 mcg | Once or twice daily | Subcutaneous, near the injury site |
| DSIP | 100–300 mcg | Daily, or 5 days on / 2 days off | Afternoon or early evening, 4–6 PM, not at bedtime |
- BPC-157: The Playbook phase framework runs this compound solo for at least two weeks before DSIP is added.
- DSIP: The Playbook phase framework introduces DSIP at 100 mcg, the lowest dose. The report that doses above 300 mcg can worsen sleep is community practice rather than a trial finding: the human DSIP record is three small trials from the 1980s–90s, 6 to 25 participants each. All documented human DSIP exposure is intravenous; the subcutaneous route has no clinical study behind it.
- Duration
- An 8-week minimum using the phase framework: weeks 1–3 BPC-157 solo, weeks 4–6 add DSIP at its lowest dose, weeks 7–8 evaluate whether the combination earns its cost and complexity.
Mixing each compound
- 10 units = 0.25 mg
- 20 units = 0.5 mg
- 30 units = 0.75 mg
- 40 units = 1 mg
- 60 units = 1.5 mg
- 10 units = 100 mcg
- 20 units = 200 mcg
- 30 units = 300 mcg
Week by week
BPC-157
- Week 1–2
Subtle. Reduced inflammation, warmth or increased blood flow near the injection site, slight pain reduction. Some people feel nothing yet. The Playbook describes this as normal.
- Week 3–4
Noticeable improvement in most reports. Pain drops on movements that previously hurt, range of motion improves, swelling decreases.
- Week 5–6
People describe significant functional recovery for acute injuries in this window. Chronic injuries may need a second cycle.
- Week 6–8+
For stubborn or chronic problems, a second cycle after a 2–4 week break often brings further improvement. Chronic tendinopathy may need two full cycles.
- After stopping
Benefits generally persist. The Playbook frames this as tissue actually repairing rather than pain being masked.
DSIP
- Nights 1–3
Subtle or nothing. Some notice slightly easier sleep onset or better morning alertness; many notice nothing. Do not increase the dose yet.
- Days 4–7
Deeper sleep, fewer middle-of-the-night awakenings, more vivid dreaming, described in our sources as a positive sign of normalising sleep architecture. Morning energy improves.
- Week 2–3
Full benefits. Noticeably more restorative sleep, better daytime energy and mood, improved stress resilience. Some report reduced caffeine dependence.
- Week 4+
Benefits plateau. Consider cycling off. Many find improvements persist for days to weeks after stopping.
- After stopping
No rebound insomnia and no withdrawal reported, the key difference from pharmaceutical sleep aids. Sleep may gradually return to baseline in people with chronic underlying issues.
What it costs
- BPC-157: $80–120 per 4–6 week cycle (two 5 mg vials)
- DSIP: $30–50 per 2–4 week cycle (one 2 mg vial)
These figures are published over different cycle lengths, so Claritide does not add them into one number. Log a vial and the cost engine will tell you what this stack costs you per week, from what you actually paid.
Cautions
- Zero interaction data exists for this pairing. Absence from an interaction list means nobody studied it, not that it is safe.
- DSIP was voted down by FDA's advisory committee 6–7–1 on 24 July 2026. It is the only one of the seven 2026 peptides to be rejected.
- The DSIP human record includes hypotension as a serious adverse effect, including progressive hypotension on re-injection, and a documented ACE-inhibitor mechanism: DSIP is metabolised by peptidyl dipeptidase A.
- BPC-157's animal toxicity work showed altered clotting parameters and raised ALT, glucose and triglycerides. No carcinogenicity study of BPC-157 exists, and no complete reproductive-development study exists.
- Every compound added is another variable of uncertain purity from an unregulated source. If something goes wrong you may not know which vial caused it.
- Get baseline bloodwork before starting and retest at week 8. The Playbook calls this non-negotiable for stacking.
- Maximum two peptides simultaneously for beginners.
Absence from this list does NOT mean safety. It means lack of research.
Every stack here is free to read, and it stays free. Your own schedule, vials and log live in the app: Claritide for iPhone.